Beijing, China, March 6, 2026 — Gan & Lee Pharmaceuticals. (hereinafter referred to as "Gan & Lee", stock code: 603087.SH) officially announced the appointment of Mr. Qi WANG as Executive Vice President & Chief Financial Officer (EVP & CFO). In this role, Mr. WANG will oversee the company's financial strategic planning, capital market operations, and investment and financing management. He will also lead the development of the company's digital systems, further solidifying its financial foundation and driving a comprehensive upgrade of its operational and management systems.

Mr. WANG brings over fifteen years of deep experience in the healthcare industry and capital markets. Prior to joining Gan & Lee, he spent a significant portion of his career at the Investment Banking Management Committee of CITIC Securities, focusing on providing a full range of capital market services for the healthcare sector. He has extensive experience in Initial Public Offerings (IPOs), refinancing, mergers, acquisitions, and restructuring. Mr. WANG successfully led and managed several IPOs and capital projects for numerous well-known biopharmaceutical companies. Notably, he served as the sponsor representative for Gan & Lee's IPO and subsequent refinancing projects. With years of dedication to the industry, Mr. WANG possesses sharp insight into the dynamics of the healthcare sector, the competitive landscape, and capital market trends.

Mr. WANG holds a Master's degree in Management from Shanghai Jiao Tong University and a Bachelor's degree from Shanghai University of Finance and Economics, equipping him with systematic financial knowledge and a forward-looking management perspective.

Against the backdrop of the company's ongoing strategy to deepen innovation and globalization, Gan & Lee has recently undertaken a systematic upgrade of its core management team. Following the appointments of Dr. Ting JIA as Chief Medical Officer and Dr. Qiang WANG as Chief Strategy Officer, the company has completed significant strategic deployments in global clinical development and strategic collaboration. The addition of Mr. Qi WANG will accelerate the deep integration of financial management with business development. Through data-driven management innovation, he will enhance resource allocation efficiency, continuously injecting strong momentum into Gan & Lee's high-quality development. The professional backgrounds of these three appointees—focusing respectively on global clinical development, global strategic partnerships, and capital strategy—are expected to create deep synergies. Together, they will serve the company's strategic linkage of "R&D Innovation - Global Operations - Capital Empowerment," promoting a systematic upgrade of overall operations and resource allocation.

Dr. Wei CHEN, Chairman of the Board and Chief Executive Officer, commented that in the current era where innovation and global competition are intertwined in the pharmaceutical industry, systematic financial planning and capital synergy have become crucial pillars supporting strategic execution. He stated that Mr. Qi WANG's addition will form an organic collaboration with the overseas clinical R&D team led by Dr. Ting JIA and the business strategy team led by Dr. Qiang WANG, collectively propelling Gan & Lee forward steadily within the global pharmaceutical value chain.

About Gan & Lee

Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company and the first in China to master industrial-scale manufacturing technologies for recombinant insulin analogs. The Company has established a comprehensive insulin research and development pipeline.

Currently, Gan & Lee offers six core insulin products, including five insulin analogs: insulin glargine injection (Basalin^®; EU brand name Ondibta^®), insulin lispro injection (Prandilin^®; EU brand name: Bysumlog^®), insulin aspart injection (Rapilin^®; EU brand name: Dazparda^®), premixed insulin lispro protamine suspension injection (25R) (Prandilin^®25), and insulin aspart 30 injection (Rapilin^®30); as well as one human insulin product, premixed human insulin protamine suspension injection (30R) (Similin^®30), together with related delivery devices. These products cover the long-acting, rapid-acting, and premixed insulins.

In China's second round of national volume-based procurement for insulin, Gan & Lee ranked first among selected companies by contracted volume for insulin analogs, further strengthening its domestic market position. In parallel, the Company continues to advance its international expansion. Insulin glargine injection has received marketing authorization from the European Commission (EC), while for insulin lispro injection and insulin aspart injection, it has received the positive opinion from CHMP of EMA. Gan & Lee is steadily progressing toward its goal of becoming a key global participant in the field of metabolic diseases.

Looking forward, Gan & Lee is committed to achieving comprehensive coverage across the diabetes treatment landscape and further enhancing its competitive position in this therapeutic area. The Company will also actively pursue the development of innovative chemical drugs and biologics, with a strategic focus on metabolic diseases, cardiovascular diseases, and other therapeutic areas.